Do you have high-risk essential thrombocythemia (ET) that has not responded adequately to, or you cannot tolerate, hydroxycarbamide (hydroxyurea)?

You may be eligible to participate in a clinical research study evaluating an investigational oral treatment designed to help control elevated platelet counts.

Participation includes:

Daily oral study medication for up to 12 months

Regular clinic visits and blood tests

Monthly symptom questionnaires

Interested in participating? Learn more and see if you qualify.